Last updated: July 9, 2026
NOVO NORDISK v. SUN PHARMA (3:15-cv-01287): Litigation Summary, Patent Claims, and Commercial Impact
Executive summary: In Novo Nordisk Inc. v. Sun Pharmaceutical Industries Limited, No. 3:15-cv-01287, the parties litigated ANDA-related patent infringement under 35 U.S.C. § 271(e)(2) and associated Hatch-Waxman procedures. The dispute centers on whether Sun’s generic/bioequivalent drug entry infringes one or more listed Orange Book patents covering Novo Nordisk’s branded product. The case’s business impact is measured by (1) the patent barriers preventing FDA approval or launch, (2) the likelihood that other generic entrants can launch around the same estate, and (3) whether the litigation resulted in a design-around strategy, an IP license/settlement, or an injunction.
No further case-specific details (captioned patents-in-suit, claim construction, dispositive rulings, settlement terms, and timeline milestones) can be produced from the docket identifier alone.
What patents protect Novo Nordisk drugs in ANDA litigation filed as 3:15-cv-01287?
Featured snippet: This matter is an ANDA patent litigation case where the patents asserted are typically those listed in FDA’s Orange Book for the reference listed drug (RLD), and infringement is assessed under § 271(e)(2) based on filing of an ANDA.
How § 271(e)(2) shapes the patent issues
Section 271(e)(2) makes infringement turn on the ANDA’s proposed product and whether it falls within the scope of the patents-in-suit. Courts commonly litigate:
- Whether the asserted claims are valid
- Whether the proposed ANDA product infringes (often including composition, method, and/or formulation claims)
- Whether the patents are enforceable and whether any defenses apply (e.g., obviousness, anticipation, indefiniteness)
Patent categories typically asserted in this type of dispute
In Orange Book-centered ANDA cases, the “patents in suit” often include at least one of:
- Composition of matter
- Method of use
- Formulation/composition claims (e.g., controlled release, stabilizers)
- Manufacturing/process claims (less common but appears in certain estates)
- Device or delivery-system claims (only if the RLD’s patent list includes them)
What is the litigation timeline for Novo Nordisk Inc. v. Sun Pharma 3:15-cv-01287?
Featured snippet: A docket-numbered Hatch-Waxman suit generally follows a sequence: complaint and infringement allegations, scheduling order, Markman/claim construction, summary judgment or trial (if any), and either a final judgment or settlement-driven resolution.
What matters most commercially in the timeline
For licensing and launch planning, the high-leverage milestones are:
- Initial TRO/PI requests and outcomes (often dispositive for launch timing)
- Claim construction decisions (frequently narrow or broaden infringement)
- Early summary judgment (validity/infringement)
- Stipulated dismissal or settlement filings (in most pharma settlements)
- Post-judgment compliance with injunction terms (if any)
When does exclusivity end for the Novo Nordisk product targeted by 3:15-cv-01287?
Featured snippet: Hatch-Waxman exclusivity and Orange Book patent expiry do not automatically align. Launch eligibility depends on the latest of: patent expiration, any period of pediatric exclusivity, and the expiration of non-patent exclusivities (e.g., 5-year/7-year exclusivity for the RLD’s approval pathway).
Practical exclusivity framework
Launch planning usually requires mapping:
- 5-year exclusivity (new chemical entity or new drug product)
- 7-year exclusivity (for new active ingredient not previously approved)
- 3-year exclusivity (new clinical investigations or other qualifying changes)
- 180-day ANDA exclusivity (for first-filer or second-filer depending on procedural history)
- Patent expiry dates for each listed patent
What happens if Sun files a Paragraph IV challenge in cases like 3:15-cv-01287?
Featured snippet: A Paragraph IV notice triggers a 30-month stay and enables the brand to sue quickly. If the court invalidates patents or finds no infringement, the generic can often proceed subject to FDA requirements.
Core decision points after a Paragraph IV notice
- Did the ANDA qualify for the automatic 30-month stay?
- Were patents found invalid or not infringed?
- Did the parties enter a settlement that modifies entry timing?
How strong was Novo Nordisk’s patent estate in 3:15-cv-01287?
Featured snippet: Strength is evaluated case-by-case on claim scope, prior art/obviousness posture, and court constructions. A litigation-specific strength assessment requires the asserted patents and claim rulings.
What drives strength assessments in court
- Validity: anticipation/obviousness posture, secondary considerations, and disclosure sufficiency
- Infringement: whether the ANDA product meets each limitation
- Indefiniteness and written description: in formulation and method claims
- Prosecution history estoppel: narrowing during prosecution
Which companies are challenging similar patents alongside Sun in ANDA litigation like this?
Featured snippet: ANDA estates often face coordinated challenges by multiple generic firms, but litigation-identifying details require the patents asserted and the procedural history in this specific case.
Competitive implications
Even if Sun loses, other filers may:
- Use different carve-outs
- Pursue different paragraph IV challenges
- Attempt design-arounds against narrower claim constructions
What formulations or dosage forms were implicated in Novo Nordisk v. Sun Pharma?
Featured snippet: Litigation typically ties to the proposed ANDA dosage form, strength, and route of administration reflected in the ANDA’s proposed label.
Design-around pathways when formulations are at issue
For formulation or method patents, design-arounds may include:
- Changing excipient systems or stabilizers
- Switching salt forms (if applicable)
- Altering release profile (if a controlled-release claim is asserted)
- Avoiding a claimed patient population or dosing regimen (for method claims)
What generic entry risks exist for Sun Pharma after 3:15-cv-01287?
Featured snippet: Post-litigation risk is determined by whether remaining patents still cover the proposed ANDA product, and whether any appellate pathways or continued injunction effects persist.
Risk scenarios
- Patents upheld: entry blocked until expiration or license
- Patents invalidated/not infringed: entry possible after FDA approval and any remaining patents
- Settlement: entry likely occurs on the settlement timetable, with potential market carve-outs
How does the Orange Book status of the relevant Novo Nordisk RLD affect launch timing?
Featured snippet: Orange Book listings define the legal landscape for ANDA challenges. The “patents-in-suit” are typically limited to those listed for the RLD and listed in the brand’s lawsuit.
Business use of Orange Book mapping
A launch plan typically requires a patent-by-patent matrix:
- Patent number
- Patent type (composition/method/formulation)
- Expiration date
- Claimed product coverage (dosage form/strength)
- Litigation outcome status
What settlement terms or consent judgments changed entry timing in 3:15-cv-01287?
Featured snippet: Settlement outcomes in Hatch-Waxman disputes often determine the effective launch date, entry/marketing limits, and sometimes ongoing supply.
Key settlement levers (when present)
- Payment for delay (if any)
- Licensed entry date
- Carve-outs on dosage strengths or indications
- Covenants not to sue after specified events
- Stipulated dismissal conditioned on timing
Key Takeaways
- Case type: Hatch-Waxman ANDA patent litigation under § 271(e)(2).
- Core commercial lever: whether Sun’s proposed ANDA product infringes and whether the asserted Orange Book patents are upheld.
- Commercial outcome drivers: claim construction, validity posture, and any settlement or injunction terms.
- Actionability constraint: the litigation’s patent list, rulings, and resolution must be tied to the case record; the docket number alone is insufficient to produce a patent-accurate analysis.
FAQs
- What is the usual role of claim construction in ANDA patent cases like Novo Nordisk v. Sun Pharma?
- How do courts treat method-of-use claims in § 271(e)(2) litigation?
- Do settlements in Hatch-Waxman cases typically bind future generic filers?
- How is “no infringement” determined when the ANDA label differs from the branded label?
- What happens to remaining Orange Book patents if some are invalidated or found not infringed?
References (APA)
No sources were cited because the request specifies only the case number without providing the underlying docket record or identifying information needed to cite case documents accurately.
